Medication-related osteonecrosis of the jaws in a patient treated with Pembrolizumab: Report of a case and review of the literature

Oral Oncol. 2024 Jun:153:106825. doi: 10.1016/j.oraloncology.2024.106825. Epub 2024 May 2.

Authors

Marco Nisi¹, Maria Chiara Pioli², Chiara Cinquini², Rossana Izzetti²

Affiliations

¹ Department of Surgical Pathology, Medicine, Molecular and Critical Area, University of Pisa, Pisa, Italy. Electronic address: marco.nisi@unipi.it.
² Department of Surgical Pathology, Medicine, Molecular and Critical Area, University of Pisa, Pisa, Italy.

PMID: 38692151
DOI: 10.1016/j.oraloncology.2024.106825

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Aged
Antibodies, Monoclonal, Humanized* / adverse effects
Antineoplastic Agents, Immunological / adverse effects
Female
Humans
Jaw Diseases / chemically induced
Male
Middle Aged
Osteonecrosis* / chemically induced

Substances

pembrolizumab